New hope for EGFR lung cancer: first human trial of ANS02 begins
NCT ID NCT07538804
First seen May 03, 2026 · Last updated May 12, 2026 · Updated 1 time
Summary
This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 294 adults with good organ function and measurable disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Guangzhou, Guangdong, China
-
Research Site
Harbin, Heilongjiang, China
-
Research Site
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.